sitagliptin glp 1 agonist Frontiers Oral GLP-1-Based Therapeutics in the
Description
By 2024, Ozempic had surpassed Trulicity, also approved for type 2 diabetes (not obesity) to make up the largest share of GLP-1 prescriptions and spending (39% in 2024)
& Diekman, B
95% C.I
doi: 10.1111/dom.15226
Frequently Asked Questions Is GLP-1 microdosing considered off-label use
Follow me for more GLP-1 advice you wont hear anywhere else
